Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs) [1].
Labeling in vivo:
1. Use the rat brain tumor model produced by the inoculation of resuspended tumor cells into the frontal rat brain. Feed animals according to your normal protocol.
2. Intravenous injection of 5 mg/kg body weight talaporfin sodium, the concentration of the talaporfin sodium is 5 mg/1 ml 0.9% saline.
3. For the control group, intraperitoneal injection of 100 mg/kg body weight 5-ALA, the concentration of the 5-ALA is 20 mg/1 ml 0.9% saline.
4. Obtain the tissue samples corresponding to the tumor (or edema) brain tissue with 5 mm thickness.
5. The samples are well homogenized with 1 ml of 100% dimethyl sulfoxide (DMSO) and the 100 ul aliquots of the supernatant are put into each well of a 96-well plate.
6. Measure the relative fluorescence intensities of the samples by using a microplate readerin emission wavelength of 670 ±10 nm. The relative fluorescence intensities of the samples (a.u.) were normalized to the relative fluorescence intensities per 1 g-weight of the samples (a.u.).
| Animal Model: | Rat brain tumor model[1] |
| Dosage: | 5 mg/kg |
| Administration: | Intravenous injection |
| Result: | Showed high fluorescence intensity and retention in brain tumor differentiated from vasogenic edema. |
